-In 481 patients presenting with a first flare and confirming MRI, but no definitive diagnosis.
In the interim analysis, the proportion of patients developing clinically definite multiple sclerosis (re: a second flare) was 43 percent in the placebo group compared with 25 percent in the Copaxone group, Teva said.
For those that received a clinical diagnosis of MS- the second attack was delayed to 722 days, vs. the 2nd attack average of 366 days in the placebo group-
http://www.reuters.com/article/health-S ... 03?sp=true
My husband was prescribed Copaxone after his first attack in March 2007. We're coming up on a year with no progression and no second attack.
best,
AC
Copaxone cuts risk of developing MS-
- cheerleader
- Family Elder
- Posts: 5361
- Joined: Mon Sep 10, 2007 2:00 pm
- Location: southern California
Copaxone cuts risk of developing MS-
Husband dx RRMS 3/07
dx dual jugular vein stenosis (CCSVI) 4/09
http://ccsviinms.blogspot.com
dx dual jugular vein stenosis (CCSVI) 4/09
http://ccsviinms.blogspot.com
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2490 Views
-
Last post by NHE
-
- 6 Replies
- 7052 Views
-
Last post by ElliotB
-
- 0 Replies
- 1410 Views
-
Last post by NHE
-
- 0 Replies
- 3687 Views
-
Last post by NHE
-
- 0 Replies
- 3392 Views
-
Last post by NHE
-
- 1 Replies
- 1114 Views
-
Last post by NHE
-
- 11 Replies
- 3500 Views
-
Last post by NHE
-
- 1 Replies
- 1658 Views
-
Last post by NHE
-
- 0 Replies
- 1570 Views
-
Last post by NHE